国家“重大新药创制”科技重大专项重点关注靶点分析解读——PI3K-Akt-mTOR通路

Analysis of Important Targets in National Key Subjects of New Drug Innovation——PI3K-Akt-mTOR Pathway

由磷脂酰肌醇3-激酶(PI3K)、丝氨酸/苏氨酸蛋白激酶(Akt)和哺乳动物雷帕霉素靶蛋白(mTOR)组成的PI3K-Akt-mTOR通路是细胞内非常重要的信号转导途径,该通路的紊乱会引起一系列的疾病,包括癌症、神经病变、自身免疫性疾病和血液淋巴系统疾病。近年来,PI3K-Akt-mTOR通路作为药物靶点备受关注。结合汤森路透数据库资源——Thomson Reuters Integrity和Cortellis for Competitive Intelligence,对PI3K-Akt-mTOR通路的机制、相关药物研究进展、适应证、研发公司、交易、专利、文献等情报进行了数据层面的分析。

The PI3K-Akt-mTOR pathway is composed of phosphatidyl-inositol-3-kinase （PI3K）, Ser/Thr kinase Akt and mammalian target of rapamycin （mTOR）. It is an important signal transduction pathway in cells. The disorder of PI3K-Akt-mTOR pathway could lead to some diseases, including cancer, neuropathy, autoimmune disease, as well as diseases of hematological and lymphatic system. Recently, PI3K-Akt-mTOR pathway has been paid much attention in pharmaceutical field. The intelligence of PI3K-Akt-mTOR pathway, including mechanism, research progress of the related drugs, indication, originator, deals, patents and references, have been analyzed by Thomson Reuters Integrity and Cortellis for Competitive Intelligence.